Status: Recruiting
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Participants needed: 61
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Radiopharm Theranostics, LtdUpdated: Mar 27, 2026Locations: 4
Eligibility criteria
Willing and able to provide informed consent prior to start of any study procedu... [+2]
Participants must have documented disease progression during or after their most... [+44]